Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce
inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic
inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp)
inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic
inflammation as well as P-gp overexpression. The goal of this study is to therefore see
whether Verapamil may be used to treat CRS.
Phase:
N/A
Details
Lead Sponsor:
Benjamin Bleier Massachusetts Eye and Ear Infirmary